Edge Wealth Management LLC Grows Holdings in iShares Nasdaq Biotechnology ETF (IBB)


Edge Wealth Management LLC grew its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 252.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,021 shares of the financial services provider’s stock after purchasing an additional 36,559 shares during the period. iShares Nasdaq Biotechnology ETF makes up about 1.4% of Edge Wealth Management LLC’s holdings, making the stock its 23rd largest holding. Edge Wealth Management LLC owned about 0.07% of iShares Nasdaq Biotechnology ETF worth $4,920,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IBB. Morgan Stanley lifted its holdings in shares of iShares Nasdaq Biotechnology ETF by 3.7% during the 3rd quarter. Morgan Stanley now owns 4,026,110 shares of the financial services provider’s stock valued at $490,944,000 after acquiring an additional 143,209 shares in the last quarter. Alliancebernstein L.P. grew its holdings in iShares Nasdaq Biotechnology ETF by 36.2% during the 3rd quarter. Alliancebernstein L.P. now owns 737,179 shares of the financial services provider’s stock valued at $89,892,000 after buying an additional 195,746 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in iShares Nasdaq Biotechnology ETF by 4.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 670,311 shares of the financial services provider’s stock valued at $81,736,000 after buying an additional 31,175 shares in the last quarter. First Republic Investment Management Inc. grew its holdings in iShares Nasdaq Biotechnology ETF by 2.3% during the 3rd quarter. First Republic Investment Management Inc. now owns 242,318 shares of the financial services provider’s stock valued at $29,548,000 after buying an additional 5,457 shares in the last quarter. Finally, Credit Suisse AG boosted its position in shares of iShares Nasdaq Biotechnology ETF by 1,228.8% during the 3rd quarter. Credit Suisse AG now owns 224,782 shares of the financial services provider’s stock valued at $27,410,000 after acquiring an additional 207,866 shares during the last quarter. Institutional investors own 64.33% of the company’s stock.

Shares of IBB traded up $0.14 during trading hours on Friday, reaching $109.04. 223,772 shares of the company’s stock traded hands, compared to its average volume of 2,745,966. iShares Nasdaq Biotechnology ETF has a 12 month low of $89.01 and a 12 month high of $122.97.

WARNING: This story was published by Fairfield Current and is owned by of Fairfield Current. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.fairfieldcurrent.com/news/2019/01/11/edge-wealth-management-llc-grows-holdings-in-ishares-nasdaq-biotechnology-etf-ibb.html.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *